M
Maria Drobnjak
Researcher at Memorial Sloan Kettering Cancer Center
Publications - 5
Citations - 3295
Maria Drobnjak is an academic researcher from Memorial Sloan Kettering Cancer Center. The author has contributed to research in topics: Homologous recombination & Gene. The author has an hindex of 5, co-authored 5 publications receiving 3128 citations.
Papers
More filters
Journal ArticleDOI
A multigenic program mediating breast cancer metastasis to bone.
Yibin Kang,Peter M. Siegel,Weiping Shu,Maria Drobnjak,Sanna M. Kakonen,Carlos Cordon-Cardo,Theresa A. Guise,Theresa A. Guise,Joan Massagué +8 more
TL;DR: Overexpression of this bone metastasis gene set is superimposed on a poor-prognosis gene expression signature already present in the parental breast cancer population, suggesting that metastasis requires a set of functions beyond those underlying the emergence of the primary tumor.
Journal Article
17-Allylamino-17-demethoxygeldanamycin Induces the Degradation of Androgen Receptor and HER-2/neu and Inhibits the Growth of Prostate Cancer Xenografts
David B. Solit,Fuzhong F. Zheng,Maria Drobnjak,Pamela N. Munster,Brian Higgins,David Verbel,Glenn Heller,William P. Tong,Carlos Cordon-Cardo,David B. Agus,Howard I. Scher,Neal Rosen +11 more
TL;DR: It is demonstrated that, at a tolerable dose, inhibition of Hsp90 function by 17-AAG results in a marked reduction in HER2, AR, and Akt expression and inhibition of prostate tumor growth in mice, suggesting that this drug may represent a new strategy for the treatment of prostate cancer.
Journal Article
Cooperative Effects of p53 and pRB Alterations in Primary Superficial Bladder Tumors
Carlos Cordon-Cardo,Zuo-Feng Zhang,Guido Dalbagni,Maria Drobnjak,Elizabeth Charytonowicz,Shi Xue Hu,Hong Ji Xu,Victor E. Reuter,William F. Benedict +8 more
TL;DR: Study of superficial transitional cell carcinomas of the urinary bladder by immunohistochemical analysis suggests that alterations of p53 and pRB have a cooperative negative effect on both progression and survival in primary bladder cancer.
Journal ArticleDOI
HDM2 Protein Overexpression and Prognosis in Primary Malignant Melanoma
David Polsky,Kate Melzer,Carole Hazan,Katherine S. Panageas,Klaus J. Busam,Maria Drobnjak,Hideko Kamino,Joanna Spira,Alfred W. Kopf,Alan N. Houghton,Carlos Cordon-Cardo,Iman Osman +11 more
TL;DR: HDRM2 overexpression appears to be an independent predictor of survival for patients with primary melanoma; however, larger prospective studies are required for validation.
Journal ArticleDOI
Bi-allelic alterations in DNA repair genes underpin homologous recombination DNA repair defects in breast cancer
Robert W. Mutter,Robert W. Mutter,Nadeem Riaz,Charlotte K.Y. Ng,Rob Delsite,Salvatore Piscuoglio,Marcia Edelweiss,Luciano G. Martelotto,Rita A. Sakr,Tari A. King,Dilip Giri,Maria Drobnjak,Edi Brogi,Ranjit S. Bindra,Ranjit S. Bindra,Giana Bernheim,Raymond S. Lim,Pedro Blecua,Alexis Desrichard,Daniel S. Higginson,Russell Towers,Ruomu Jiang,William Lee,Britta Weigelt,Jorge S. Reis-Filho,Simon N. Powell +25 more
TL;DR: The findings indicate the importance of a comprehensive genetic assessment of bi‐allelic alterations in the HR pathway to deliver a precision medicine‐based approach to select patients for therapies targeting tumour‐specific DNA repair defects.